Effects of High-Flow Nasal Cannula Therapy Assessed by Electrical Impedance Tomography

Electrical Impedance Tomography Clinical Trial

Official title:

Effects of High-Flow Nasal Cannula Therapy on Lung Recruitment and Lung Strain Change Assessed by Electrical Impedance Tomography

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04245241
• Other study ID #: EIT-HFNC
• Status: Completed
• Start date: May 1, 2018
• Est. completion date: November 1, 2019

Study information

• Verified date: January 2020
• Source: Peking Union Medical College Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study aimed to determine the effects of HFNC therapy on lung recruitment and lung strain change assessed by electrical impedance tomography (EIT)

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: November 1, 2019
• Est. primary completion date: July 1, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

• Inclusion Criteria:

• Patient who received a HENC therapy within 24 h after the extubation

Exclusion Criteria:

• Aged <18 years

• Pregnancy

• Body mass index (BMI) over 50 kg/m2

• ribcage malformation .any contraindication of using EIT monitoring (automatic implantable cardioverter defibrillator, chest skin injury, etc.).

Related Conditions & MeSH terms

• Electrical Impedance Tomography
• High-flow Nasal Cannula

Intervention

Other:
• High-flow nasal cannula (HFNC)
24 patients who receiving HFNC within 24 hours after extubation were prospectively enrolled in this study. EIT was used to monitor regional lung ventilation distributions at baseline (conventional oxygen therapy) and three flow rate levels of HFNC therapy (20, 40 and 60 L/min).

Locations

Country	Name	City	State
China	Department of Critical Care Medicine, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences,	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Peking Union Medical College Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	lung regional ventilation distribution	lung regional ventilation distribution measured by EIT	minute 80